T
Troy H. Guthrie
Researcher at University of Florida
Publications - 43
Citations - 1809
Troy H. Guthrie is an academic researcher from University of Florida. The author has contributed to research in topics: Romiplostim & Thrombocytopenic purpura. The author has an hindex of 17, co-authored 43 publications receiving 1720 citations. Previous affiliations of Troy H. Guthrie include University of Florida Health Science Center & Florida State University.
Papers
More filters
Journal ArticleDOI
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel A. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère,Alan E. Lichtin,Michael D. Tarantino,Howard R. Terebelo,Jean François Viallard,Francis J. Cuevas,Ronald S. Go,David H. Henry,Robert L. Redner,Lawrence Rice,Martin R. Schipperus,D. Matthew Guo,Janet L. Nichol +31 more
TL;DR: Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenECTomised patients with ITP and treatment safety was good.
Journal ArticleDOI
Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy.
TL;DR: The combination of CDDP and Dox is highly effective in BC and SC cancers of the skin and by itself can produce long unmaintained remissions, but when combined with a second modality of therapy, it is capable of producing not only long unmaintainable CRs but probable cures in the majority of pts.
Journal ArticleDOI
Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura
Harry W. Snyder,Sharon K. Cochran,Joseph P. Balint,Juergen H. Bertram,Abraham Mittelman,Troy H. Guthrie,Frank R. Jones +6 more
TL;DR: The degree of effectiveness of protein A immunoadsorption therapy in patients with treatment-resistant ITP is promising and further controlled studies in this patient population are warranted.
Journal ArticleDOI
Treatment of cancer chemotherapy‐associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma
Snyder Hw,A. Mittelman,Arsinur Oral,Gerald L. Messerschmidt,David H. Henry,Stefan Korec,Juergen H. Bertram,Troy H. Guthrie,David Ciavarella,David Wuest,William Perkins,Joseph P. Balint,Sharon K. Cochran,Reneé L. Peugeot,Frank R. Jones +14 more
TL;DR: C‐TTP/HUS is a condition involving thrombocytopenia, microangiopathic hemolytic anemia, and progressive renal dysfunction that develops in 2–10% of patients with a history of malignant neoplasms treated with certain chemotherapeutic agents.
Journal ArticleDOI
Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin.
TL;DR: The results indicate the combination of cisplatin and doxorubicin has significant activity in both advanced BCC and SCC of the skin, and a portion of patients treated with the combination achieve a long‐term unmaintained disease‐free state.